Coronary thrombosis
diseaseOn this page
Also known as coronary vessel thrombotic diseasethrombotic disease of coronary vessel
Summary
Coronary thrombosis (MONDO:0006716) is a disease with 11 GWAS associations across 1 studies and 13 clinical trials. Top therapeutic interventions include pantoprazole. A subtype of thrombotic disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- GWAS associations: 11
- Clinical trials: 13
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | coronary thrombosis |
| Mondo ID | MONDO:0006716 |
| EFO | EFO:1000883 |
| MeSH | D003328 |
| DOID | DOID:11847 |
| ICD-10-CM | I22 |
| SNOMED CT | 398274000 |
| UMLS | C0010072 |
| MedGen | 3625 |
| MedDRA | 10011108 |
| Anatomy (UBERON) | UBERON:0005985 |
| Is cancer (heuristic) | no |
Also known as: coronary vessel thrombotic disease · thrombotic disease of coronary vessel
Data availability: 11 GWAS associations (1 study).
Disease family
This is a subtype of thrombotic disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › thrombotic disease › coronary thrombosis
Related subtypes (7): marantic endocarditis, portal vein thrombosis, intracranial thrombosis, heparin-induced thrombocytopenia, acquired purpura fulminans, isolated splenic vein thrombosis, isolated mesenteric vein thrombosis
Genetics & variants
GWAS landscape
11 GWAS associations across 1 studies. Top hits map to 6 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs35150895 | 6e-07 | RPS23P3 - RNU6-699P | A | 3.45 |
| rs7784948 | 2e-06 | TMEM229A - SSU72L6 | T | 2.58 |
| rs72935945 | 3e-06 | METTL24 | T | 2.23 |
| rs4714457 | 5e-06 | NCR2 - FOXP4-AS1 | C | 2.13 |
| rs2438162 | 5e-06 | ISCA1P6 - LINC01854 | A | 2.04 |
| rs9998058 | 6e-06 | PALLD | C | 2.71 |
| rs10421769 | 6e-06 | GPATCH1 | C | 0.42 |
| rs3849111 | 7e-06 | EPB41L4B | A | 0.43 |
| rs1965492 | 9e-06 | SCAPER | C | 1.98 |
| rs56076602 | 9e-06 | DSCAM | G | 2.78 |
| rs56222681 | 9e-06 | MIR1202 - SNORD28B | A | 2.3 |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST011434 | Li Y | 2021 | 42 | 0 | Donor genetic variants as risk factors for thrombosis after liver transplantation: A genome-wide association study. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 1 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 10 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 11 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 0 |
Functional consequences
| Consequence | Count |
|---|---|
| intron_variant | 7 |
| intergenic_variant | 3 |
| stop_gained | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs35150895 | 4 | 66580115 | G>A | 0.054 | intergenic_variant | RPS23P3 - RNU6-699P | 6e-07 | Tier 4: intronic/intergenic |
| rs7784948 | 7 | 124429457 | G>T | 0.093 | intron_variant | TMEM229A - SSU72L6 | 2e-06 | Tier 4: intronic/intergenic |
| rs72935945 | 6 | 110334472 | C>T | 0.189 | intron_variant | METTL24 | 3e-06 | Tier 4: intronic/intergenic |
| rs4714457 | 6 | 41410254 | C>A,G,T | 0.219 | intergenic_variant | NCR2 - FOXP4-AS1 | 5e-06 | Tier 4: intronic/intergenic |
| rs2438162 | 2 | 128556655 | A>C,G,T | 0.283 | intergenic_variant | ISCA1P6 - LINC01854 | 5e-06 | Tier 4: intronic/intergenic |
| rs9998058 | 4 | 168675402 | T>A,C | 0.074 | intron_variant | PALLD | 6e-06 | Tier 4: intronic/intergenic |
| rs10421769 | 19 | 33114406 | T>A,C | 0.328 | stop_gained | GPATCH1 | 6e-06 | Tier 1: coding |
| rs3849111 | 9 | 109232442 | A>C,G,T | 0.372 | intron_variant | EPB41L4B | 7e-06 | Tier 4: intronic/intergenic |
| rs1965492 | 15 | 76480985 | C>A,G | 0.424 | intron_variant | SCAPER | 9e-06 | Tier 4: intronic/intergenic |
| rs56076602 | 21 | 40679234 | C>G,T | 0.078 | intron_variant | DSCAM | 9e-06 | Tier 4: intronic/intergenic |
| rs56222681 | 6 | 156157819 | G>A | 0.143 | intron_variant | MIR1202 - SNORD28B | 9e-06 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 13.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 8 |
| PHASE4 | 3 |
| PHASE1/PHASE2 | 1 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00713947 | PHASE4 | WITHDRAWN | Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control |
| NCT00963781 | PHASE4 | COMPLETED | Scripps Evaluation of Antiplatelet Therapies for Intermediate Duration With the Endeavor Stent (Seaside) |
| NCT01166685 | PHASE4 | COMPLETED | Safety and Efficacy Study Comparing 3 New Types of Coronary Stents |
| NCT01274234 | PHASE1/PHASE2 | COMPLETED | OCT Evaluation of Healing of COMBO Stent |
| NCT05647018 | PHASE2 | UNKNOWN | In-hospital Clinical Outcome of Deferred Stenting Versus Immediate Stenting in the Management of Acute STEMI Presenting With High Thrombus Burden. |
| NCT06565793 | Not specified | NOT_YET_RECRUITING | A MAajor RAdiation-based PCI Study in STEMI and NSTEMI |
| NCT00327041 | Not specified | UNKNOWN | Monitoring Response to Antiplatelet Therapy |
| NCT00657436 | Not specified | COMPLETED | Myeloid-Related Protein in Evaluation of Acute Chest Pain in the Emergency Departement |
| NCT00714623 | Not specified | COMPLETED | The SCRIPPS DES REAL WORLD Registry |
| NCT02591264 | Not specified | UNKNOWN | Periprocedural Myocardial Infarction: the Role of Human Neutrophil Peptide-1 to 3 |
| NCT03034148 | Not specified | COMPLETED | Platelet Acetyl Coenzyme A Carboxylase Phosphorylation in Coronary Artery Disease |
| NCT03180931 | Not specified | COMPLETED | Independent OCT Registry on Very Late Bioresorbable Scaffold Thrombosis |
| NCT06665919 | Not specified | COMPLETED | The Study of CYP2C19 Genotype-Guided Clopidogrel Treatment Models |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| PANTOPRAZOLE | 4 | 1 |
Related Atlas pages
- Drugs: Pantoprazole